BRAF V600E does not predict aggressive features of pediatric papillary thyroid carcinoma

Laryngoscope

Volumn 124, Issue 9, 2014, Pages

  Givens, Daniel J ^a   Buchmann, Luke O ^a   Agarwal, Archana M ^a   Grimmer, Johannes F ^a   Hunt, Jason P ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

BRAF V600E mutation; Papillary thyroid cancer; pediatric

Indexed keywords

B RAF KINASE;

ADOLESCENT; ADULT; ARTICLE; CANCER SIZE; CHILD; CLINICAL ARTICLE; EXON; GENE MUTATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG METASTASIS; LYMPH VESSEL METASTASIS; MICRODISSECTION; NECK METASTASIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PYROSEQUENCING; RETROSPECTIVE STUDY; THYROID CARCINOMA; THYROIDECTOMY; TUMOR INVASION;

BRAF V600E MUTATION; PAPILLARY THYROID CANCER; PEDIATRIC;

ADOLESCENT; CARCINOMA; CHILD; CHILD, PRESCHOOL; HUMANS; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; RETROSPECTIVE STUDIES; THYROID NEOPLASMS;

EID: 84906669604     PISSN: 0023852X     EISSN: 15314995     Source Type: Journal    
DOI: 10.1002/lary.24668     Document Type: Article

References (25)

1. Josefson J, Zimmerman D,. Thyroid nodules and cancers in children. Pediatr Endocrinol Rev 2008; 6: 14-23.
2. Chaukar DA, Rangarajan V, Nair N, et al. Pediatric thyroid cancer. J Surg Oncol 2005; 92: 130-133.
3. Garnett MJ, Marais R,. Guilty as charged: B-RAF is a human oncogene. Cancer Cell 2004; 6: 313-319.
4. Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by onco-genic mutations of B-RAF. Cell 2004; 116: 855-867.
5. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954.
6. Rowe LR, Bentz BG, Bentz JS,. Detection of BRAF V600E activating mutation in papillary thyroid carcinoma using PCR with allele-specific fluorescent probe melting curve analysis. J Clin Pathol 2007; 60: 1211-1215.
7. Tufano RP, Teixeira GV, Bishop J, Carson KA, Xing M,. BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. Medicine (Baltimore) 2012; 91: 274-286.
8. Lee C, Lee KC, Schneider EB, Zeiger MA,. BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis. J Clin Endocrinol Metab 2012; 97: 4559-4570.
9. Kimura ET, Nikiforova MN, Zhu Z, et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the ret/ptc-ras-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003; 63: 1454-1457.
10. Nikiforova MN, Ciampi R, Salvatore G, et al. Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. Cancer Lett 2004; 209: 1-6.
11. Kumagai A, Namba H, Saenko VA, et al. Low frequency of BRAFT1796A mutations in childhood thyroid carcinomas. J Clin Endocrinol Metab 2004; 89: 4280-4284.
12. Penko K, Livezey J, Fenton C, et al. BRAF mutations are uncommon in papillary thyroid cancer of young patients. Thyroid 2005; 15: 320-325.
13. Rosenbaum E, Hosler G, Zahurak M, Cohen Y, Sidransky D, Westra WH,. Mutational activation of BRAF is not a major event in sporadic childhood papillary thyroid carcinoma. Mod Pathol 2005; 18: 898-902.
14. Sassolas G, Hafdi-Nejjari Z, Ferraro A, et al. Oncogenic alterations in papillary thyroid cancers of young patients. Thyroid 2012; 22: 17-26.
15. Hay ID, Bergstralth EJ, Goellner JR, Ebersold JR, Grant CS,. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 1993; 114: 1050-1057.
16. Farrand K, Jovanovic L, Delahunt B, et al. Loss of heterozygosity studies revisited: prior quantification of the amplifiable DNA content of archival samples improves efficiency and reliability. J Mol Diagn 2002; 4: 150-158.
17. Vaughn CP, Zobell SD, Furtado LV, Baker CL, Samowitz WS,. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosomes Cancer 2011; 50: 307-312.
18. Gouveia C, Can NT, Bostrom A, Grenert JP, van Zante A, Orloff LA,. Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience. JAMA Otolaryngol Head Neck Surg 2013; 139: 1164-1170.
19. Xing M, Haugen BR, Schlumberger M,. Progress in molecular-based management of differentiated thyroid cancer. Lancet 2013; 381: 1058-1069.
20. Alexander EK, Kennedy GC, Baloch ZW, et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med 2012; 367: 705-715.
21. Nikiforov YE, Yip L, Nikiforova MN,. New strategies in diagnosing cancer in thyroid nodules: Impact of molecular markers. Clin Cancer Res 2013; 19: 2283-2288.
22. Powers PA, Dinauer CA, Tuttle RM, Francis GL,. The MACIS score predicts the clinical course of papillary thyroid carcinoma in children and adolescents. J Pediatr Endocrinol Metab 2004; 17: 339-343.
23. Prescott JD, Sadow PM, Hodin RA, et al. BRAFV600E status adds incremental value to current risk classification systems in predicting papillary thyroid carcinoma recurrence. Surgery 2012; 152: 984-990.
24. Nam JK, Jung CK, Song BJ, et al. Is the BRAF(V600E) mutation useful as a predictor of preoperative risk in papillary thyroid cancer? Am J Surg 2012; 203: 436-441.
25. Lin JD, Liou MJ, Chao TC, Weng HF, Ho YS,. Prognostic variables of papillary and follicular thyroid carcinoma patients with lymph node metastases and without distant metastases. Endocr Relat Cancer 1999; 6: 109-115.